Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
Nephrotic Syndrome
Interventions
DRUG

ADX-629

ADX-629 (250 milligrams) administered twice daily

Trial Locations (11)

27834

East Carolina University - Nephrology, Greenville

30110

ClinCept, LLC, Bremen

30322

Emory University - Pediatric Nephrology, Atlanta

33309

South Florida Research Institute, Lauderdale Lakes

43004

The Ohio State University (OSU) Wexner Medical Center, Columbus

43537

University of Toledo Medical Center, Toledo

71101

Northwest Louisiana Nephrology, Shreveport

80045

University of Colorado, Aurora

84765

Southern Utah Kidney and Hypertension Center, St. George

88901

Nevada Kidney Disease Hypertension Center (NKDHC), Las Vegas

91324

Amicis Research Center - Northridge, Northridge

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY